Metformin Recalled Due to Contamination With Carcinogen
No reports of adverse events related to the recall have been reported
TUESDAY, Nov. 3, 2020 (HealthDay News) -- A cancer-causing compound in the drug metformin has resulted in the recall of two lots of the drug.
Kansas City-based Nostrum Laboratories Inc., said Monday that it is voluntarily recalling its metformin HCl extended release tablets, USP 750 mg, according to a notice from the U.S. Food and Drug Administration. No reports of adverse events related to the recall have been reported, the company said.
These tablets are tainted with higher-than-safe levels of the chemical nitrosamine, or NDMA. NDMA is a possible carcinogen, according to the U.S. Environmental Protection Agency.
The affected product is packaged in HDPE bottles of 100 tablets, under NDC 29033-056-01. The affected Metformin HCl Extended Release Tablets, USP 750 mg lots are under NDC 29033-056-01, lot numbers MET200101 and MET200301, with the expiration date 05/2022. It can be identified as an off-white oblong tablet debossed with "NM7."